Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment.

40.0% of patients from the MTX non-treatment group and 18.8% from those treated with MTX developed a type of CVD, that is, defined as AP, MI, congestive HF, arrhythmia, stroke, PAD, or sudden cardiac death, with statistically significant reduction in crude analysis ( p = 0.015; Figure 2 ) and a slightly non-significant trend after adjusted analysis ( p = 0.054; Figure 3 ).

also in 109 other papers

Results for sudden cardiac death (OR 0.19, 95% CI, 0.02–1.67) and arrhythmia (OR 1.25, 95% CI, 0.36–4.14) did not reach statistical significance between the study groups ( Figure 4 ).

also in 111,027 other papers